NILE Study: Large prospective head-to-head trial finds Guardant360® is as effective as tissue testing in detecting NSCLC biomarkers1
NILE Study: Large prospective head-to-head trial finds Guardant360® is as effective as tissue testing in detecting NSCLC biomarkers1
NILE Study: Large prospective head-to-head trial finds Guardant360® is as effective as tissue testing in detecting NSCLC biomarkers1
Key Findings
Key Findings
“In a landscape where a large fraction of our patients never get their tumor genotyped because of insufficient tissue or sequential tissue testing, it would make sense to adopt a strategy where blood is used first to detect alterations.”
Dr. Vassiliki A. Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology
MD Anderson Cancer Center
“In a landscape where a large fraction of our patients never get their tumor genotyped because of insufficient tissue or sequential tissue testing, it would make sense to adopt a strategy where blood is used first to detect alterations.”
Dr. Vassiliki A. Papadimitrakopoulou
Department of Thoracic Head and Neck Medical Oncology
MD Anderson Cancer Center
Study Overview
A head-to-head, prospective, multicenter trial compared Guardant360® vs standard-of-care tissue testing for biomarker detection in 282 newly diagnosed patients with advanced NSCLC
Study Overview
A head-to-head, prospective, multicenter trial compared Guardant360® vs standard-of-care tissue testing for biomarker detection in 282 newly diagnosed patients with advanced NSCLC
Points for your practice
Points for your practice
Guardant360® performed similarly to tissue in the detection of guideline-recommended biomarkers
Guardant360® performed similarly to tissue in the detection of guideline-recommended biomarkers
Guardant360 enabled more complete biomarker assessment than tissue testing
Guardant360 enabled more complete biomarker assessment than tissue testing
Faster test results and less time waiting to make treatment decisions
Guardant360® provided test results in 9 days vs 15 days for tissue
Faster test results and less time waiting to make treatment decisions
Guardant360® provided test results in 9 days vs 15 days for tissue
Guardant360® detects more guideline-recommended biomarkers** than tissue testing
** EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutation, RET fusions, MET amplification and MET exon 14 skipping variants, and ERBB2 (HER2) mutations.
Guardant360® detects more guideline-recommended biomarkers** than tissue testing
** EGFR mutations, ALK fusions, ROS1 fusions, BRAF V600E mutation, RET fusions, MET amplification and MET exon 14 skipping variants, and ERBB2 (HER2) mutations.
NILE Study Review
Dr. Vassiliki A. Papadimitrakopoulou,
MD Anderson Cancer Center
Reference:
1. Leighl NB et al. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. 2019
MKTAMEA112020_015
Address:
3 Fusionopolis Link, # 02-11,
Nexus @ One-North,
Singapore 138543.
Telephone:
+65 63056523 / +65 63056520
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
Email:
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED